Equities

Scancell Holdings PLC

SCLP:LSE

Scancell Holdings PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)14.00
  • Today's Change-0.50 / -3.45%
  • Shares traded341.34k
  • 1 Year change9.85%
  • Beta1.1132
Data delayed at least 20 minutes, as of Nov 22 2024 16:28 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Scancell Holdings plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is a developer of immunotherapies for the treatment of cancer and infectious diseases. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2 & iSCIB2, SCOV1 and SCOV2 (COVIDITY), as well as Anti-glycan antibodies. Modi-1, which targets citrullinated cancer antigens, is the first therapeutic vaccine candidate to emerge from Scancell's Moditope platform. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company's Moditope platform. Its lead ImmunoBody cancer vaccine, SCIB1, is being developed for the treatment of patients with metastatic melanoma. The COVIDITY program, focuses on the Company's COVID-19 vaccine candidates, SCOV1 and SCOV2.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-5.86m
  • Incorporated2008
  • Employees61.00
  • Location
    Scancell Holdings PLCUnit 202 Bellhouse BuildingSanders Road, Oxford Science ParkOXFORD OX4 4GDUnited KingdomGBR
  • Phone+44 18 6558 2066Fax+44 11 5823 1863
  • Websitehttps://www.scancell.co.uk/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Arecor Therapeutics PLC4.90m-8.67m28.88m50.0028.88m50.00
Sareum Holdings Plc0.00-3.42m32.43m5.0032.43m5.00
Skinbiotherapeutics PLC161.65k-2.88m36.26m11.0036.26m11.00
Poolbeg Pharma PLC0.00-4.38m38.00m8.0038.00m8.00
Futura Medical PLC8.40m-3.75m100.75m12.00100.75m12.00
Scancell Holdings Plc0.00-5.86m134.79m61.00134.79m61.00
Faron Pharmaceuticals Oy0.00-26.30m148.85m34.00148.85m34.00
hVIVO PLC64.38m17.45m155.81m274.00155.81m274.00
4Basebio PLC596.00k-9.84m166.54m--166.54m--
Avacta Group Plc22.62m-25.89m171.73m154.00171.73m154.00
Bioventix PLC13.61m8.10m193.65m17.00193.65m17.00
Allergy Therapeutics plc55.20m-40.22m247.85m635.00247.85m635.00
Data as of Nov 22 2024. Currency figures normalised to Scancell Holdings PLC's reporting currency: UK Pound GBX

Institutional shareholders

41.80%Per cent of shares held by top holders
HolderShares% Held
Redmile Group LLCas of 20 Dec 2023268.62m28.90%
Vulpes Investment Management Pte Ltd.as of 28 Dec 2023119.91m12.90%
Data from 11 Apr 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.